ArticleImmunologic research2026
Knockdown of LncRNA NIFK-AS1 inhibits the activation of CD4 + T cells in systemic lupus erythematosus by regulating the let-7f-5p/STAT3 axis.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SLE is marked by dysregulated T cell activation, which consequently triggers the excessive generation of autoantibodies. Long non-coding RNAs (lncRNAs) may be associated with autoimmune and inflammatory diseases, and NIFK-AS1 has been found to be abnormally expressed in SLE. The aim of this study is to explore the abnormal expression and clinical role of NIFK-AS1 in SLE patients, and to investigate whether NIFK-AS1 regulates the expression of let-7f-5p to participate in the immune mechanism of SLE. This study included 88 healthy controls and 95 SLE patients and compared the expression levels of NIFK-AS1 in two groups. CD4 + T cells were extracted from the peripheral blood of patients in both groups, and the expression levels of NIFK-AS1 were overexpressed or knocked down through transfection technology. The impact of NIFK-AS1 on the activation of CD4 + T cells was also investigated. Furthermore, the relationship between the NIFK-AS1/let-7f-5p/STAT3 axis was verified through a dual-luciferase assay. Elevated levels of NIFK-AS1 were observed in both the serum and T cells of individuals with SLE. Furthermore, the expression of NIFK-AS1 is significantly correlated with the clinical indicators of SLE patients. NIFK-AS1 has a significant diagnostic effect on SLE. Functionally, the inhibition of NIFK-AS1 led to suppressed activation of healthy T cells and a reduction in the auto-reactivity of SLE-derived CD4 + T cells. Conversely, let-7f-5p inhibitor mitigated the inhibitory effects induced by NIFK-AS1 knockdown on CD4 + T cell activation. Furthermore, NIFK-AS1 promoted STAT3 expression by inhibiting let-7f-5p. The NIFK-AS1/let-7f-5p/STAT3 axis is significantly involved in T cell activation within SLE, thereby offering a promising therapeutic target for the management of this disease.
Indexed as
Identifiers
41831116What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.